Vinciguerra V, Coleman M, Pajak T F, Rafla S, Stutzman L, Gomez G, Weil M, Brunner K, Cuttner J, Nissen N, Leventhal B, Gottlieb A
Cancer Clin Trials. 1981;4(2):99-105.
The effects of chemotherapy and chemoimmunotherapy in previously treated advanced Hodgkin's disease were evaluated in a randomized study of 167 patients by CALGB. Combination chemotherapy consisted of treatment with one of three regimens with further randomization of MER (methanol extraction residue BCG) immunotherapy or no MER during chemotherapy. CVPP (CCNU, vinblastine, procarbazine, prednisone) was compared to a new combination, BAVS (bleomycin, Adriamycin, vincristine, streptozotocin), and to a third regimen consisting of alternating cycles of CVPP and BAVS. At the current analysis there is no significant difference in complete responses among the chemotherapy regimens. MER did not improve complete response frequency and was associated with significantly poorer survival for patients previously treated with chemotherapy. There was also no benefit with MER for patients with at least one pretreatment positive skin test. Because of the documented lack of therapeutic benefit and the morbidity of painful ulcers, MER treatment has been discontinued.
癌症与白血病研究组B（CALGB）在一项针对167例患者的随机研究中评估了化疗和化疗免疫疗法对既往接受过治疗的晚期霍奇金病的疗效。联合化疗由三种方案之一进行治疗，并在化疗期间进一步随机分组接受MER（甲醇提取物残渣卡介苗）免疫疗法或不接受MER。将环磷酰氨、环己亚硝脲、长春花碱、甲基苄肼、强的松（CVPP）与一种新的联合方案博来霉素、阿霉素、长春新碱、链脲佐菌素（BAVS）以及由CVPP和BAVS交替周期组成的第三种方案进行比较。在当前分析中，化疗方案之间的完全缓解率没有显著差异。MER并未提高完全缓解频率，并且与既往接受过化疗的患者生存率显著降低相关。对于至少有一次预处理阳性皮肤试验的患者，MER也没有益处。由于已证明缺乏治疗益处以及疼痛性溃疡的发病率，MER治疗已停止。
